Stockreport
Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026 [Yahoo! Finance]
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Its non-GAAP profit of $9.47 per share was 6.4% above analysts' consensus estimates. Is now the time to buy Regeneron? Find out in our full research report Regeneron (REGN) Q1 CY2026 Highlights: Revenue: $3.61 billion vs analyst estimates of $3.47 billion (19% year-on-year growth, 3.8% beat) Adjusted EPS: $9.47 vs analyst estimates of $8.90 (6.4% beat) Adjusted Operating Income: $642.9 million vs analyst estimates of $951.4 million (17.8% margin, 32.4% miss) Operating Margin: 17.8%, down from 19.5% in the same quarter last year Free Cash Flow Margin: 23.5%, down from 26.9% in the same quarter last year Market Capitalization: $74.45 billion "In the first quarter of this year, we were able to achieve strong double-digit growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Offi
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- Regeneron Pharmaceuticals (REGN) had its price target lowered by Wells Fargo & Company from $825.00 to $800.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- Regeneron Tops Q1 Estimates on Dupixent Momentum [Yahoo! Finance][Yahoo! Finance]
- Regeneron Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance][Yahoo! Finance]
- Regeneron's C5 Milestones And Autoimmune Bets Shape Future Valuation [Yahoo! Finance][Yahoo! Finance]
- Regeneron Reports First Quarter 2026 Financial and Operating Results [Yahoo! Finance][Yahoo! Finance]
- More
REGN
SEC Filings
SEC Filings
- 4/29/26 - Form 10-Q
- 4/29/26 - Form 8-K
- 4/24/26 - Form ARS
- REGN's page on the SEC website
- More